Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574481 · ClinicalTrials.gov registry record · NA
ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 524
- Enrollment target
NCT02574481: Completed NA study, sponsored by Boston Scientific Corporation.
NCT02574481 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 524 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02574481, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 524 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length. Long Lesion Substudy: to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions \>140 mm and ≤ 190 mm in length.
Primary Outcome
MAEs defined as all causes of death through 1 month, target limb major amputation through 12 months and/or target lesion revascularization (TLR) through 12 months
Interventions
- DEVICE ELUVIA (Stent Implantation)
- DEVICE Zilver PTX (Stent Implantation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2015-12 |
| Est. Completion | 2022-04-12 |
| Phase | NA |
What the finished NCT02574481 record still lists
NCT02574481 is an interventional study that assigns participants to a tested intervention. The registered 524 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which ELUVIA (Stent Implantation) is the first listed.
NCT02574481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02574481 about?
NCT02574481 is a clinical study titled "ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent". The primary objective of this trial is to evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions up to 140 mm in length. Lo...
What is the current status of trial NCT02574481?
This trial is currently completed. It is a NA study. The enrollment target is 524 participants. The study started on 2015-12. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT02574481?
The interventions under investigation include: ELUVIA (Stent Implantation) (DEVICE), Zilver PTX (Stent Implantation) (DEVICE).
Who is sponsoring clinical trial NCT02574481?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02574481's enrollment target sits among peer trials
524 189th of 2000 higher than 1,812 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia